Recursion Pharmaceuticals is trading at $4.38, with a -4.75% change, amid likely biotech-sector weakness; no clear company-specific announcement explains the October 7 decline.
- The provided sector context shows XBI down 2.50% during the session.
- Major U.S. indexes were lower as Treasury yields and oil rebounded, while investors awaited Fed minutes.
- Reuters described the cautious market setup but identified no Recursion-specific catalyst.